Mabion S.A. (WSE: MAB)

Market Cap	273.14M
Revenue (ttm)	139.86M
Net Income (ttm)	37.39M
Shares Out	16.16M
EPS (ttm)	2.31
PE Ratio	7.32
Forward PE	23.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,217
Open	16.92
Previous Close	16.98
Day's Range	16.82 - 17.02
52-Week Range	15.50 - 23.60
Beta	1.00
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 19, 2024

About Mabion

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. Mabion S.A. was founded in 2007 and is based in Konstantynów Lódzki, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 244
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: MAB

Financial Performance

In 2023, Mabion's revenue was 151.68 million, a decrease of -7.50% compared to the previous year's 163.98 million. Earnings were 41.27 million, an increase of 77.94%.